钆塞酸二钠动态增强磁共振定量评估兔肝纤维化的研究

doi:10.3969/j.issn.1006-6233.2020.08.024

Abstract
Figure/Table
References
Related Citation (6)

Download: PDF (1628 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To explore quantitative parameters obtained by dynamic contrast-enhanced magnetic resonance imaging (DCE MRI) with gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) in diagnosing and discriminating liver fibrosis (LF) in a rabbit model. Methods: LF group was established in 60 rabbits by the injection of 50% CCl4 oil solution, whereas 20 rabbits injected with normal saline served as the control group. 15 objects in the LF group and 5 in the control group were randomly selected at the end of the 4th, 5th, 6th, 15th week after injection of 50% CCl4 oil solution, respectively. All rabbits underwent pathological examination to determine the LF stage using the Metavir classification system. DCE MRI was performed, and quantitative parameters, including ^trans, K_ep , Ve, Vp and Re were measured and compared among the different LF stages. Results: In all, 16, 14, 12, 10, 11 rabbits of stage F0, F1, F2, F3 and F4, respectively, were included in this study. ^trans (r=0.913) increased, K_ep (r =-0.757) and Re (r =-0.804) decreased with LF stage progression (P<0.001), while no significant correlation was found for Ve or Vp. The AUC of ^trans was higher than that of other quantitative parameters, with an AUC of 0.96, 0.96, 0.96 and 0.99 for staging ≥F1、≥F2、≥F3、≥F4, respectively. Conclusion: Gd-EOB-DTPA DCE MRI parameters are closely associated with LF progression, indicating that this may be a promising method for quantitatively differentiating early-stage LF.

Key words： Liver fibrosis Dynamic contrast-enhanced magnetic resonance imaging Gd-EOB-DTPA Quantitative assessment

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Liping
	WU Xiuli
	HUANG Baosheng
	et al

Cite this article:

ZHANG Liping,WU Xiuli,HUANG Baosheng, et al. A Study of Gd-EOB-DTPA Dynamic Contrast Enhanced MRI in Quantitatively Assessing Liver Fibrosis in Rabbits[J]. HeBei Med, 2020, 26(8): 1333-1337.

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2020.08.024 OR http://www.hbyxzzs.cn/EN/Y2020/V26/I8/1333

[1] 朱红梅, 王勤英.非酒精性脂肪性肝病肝纤维化的诊断及治疗进展[J].临床肝胆病杂志, 2020, 36(1):178~181.
[2] Lemmer A, VanWagner LB. Assessment of advanced liver fibrosis and the risk for hepatic decompensation in patients with congestive hepatopathy[J]. Hepatology, 2018, 68(4):1633~1641.
[3] Altamirano-Barrera A, Barranco-Fragoso B, Mendez-Sanchez N. Management strategies for liver fibrosis[J]. Ann Hepatol, 2017, 16(1):48~56.
[4] Czeczok TW, Van Arnam JS, Wood LD, et al. The almost-normal liver biopsy: presentation, clinical associations and outcome[J]. Am of Surg Pathol, 2017, 41(9):1247~1253.
[5] Van Beers BE, Daire JL, Garteiser P. New imaging techniques for liver diseases[J].Hepatol, 2015, 62(3):690~700.
[6] Keller S, Sedlacik J, Schuler T, et al. Prospective comparison of diffusion-weighted MRI and dynamic Gd-EOB-DTPA-enhanced MRI for detection and staging of hepatic fibrosis in primary sclerosing cholangitis[J]. Eur Radiol, 2019, 29(2):818~828.
[7] 张豪, 邹立秋, 张凯, 等.MR多参数成像诊断肝纤维化分期的价值[J].中华放射学杂志, 2019, 53(10):900~904.
[8] De Leon-Rodriguez LM, Martins AF, Pinho MC, et al. Basic MR relaxation mechanisms and contrast agent design[J].Magn Reson Imaging, 2015, 42(3):545~565.
[9] Liu H, Liu J, Zhang Y, et al. Contrast-enhanced ultrasound and computerized tomography perfusion imaging of a liver fibrosis-early cirrhosis in dogs[J].Gastroenterol Hepatol, 2016, 31(9):1604~1610.
[10] Zhang CY, Yuan WG, He P, et al. Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets[J]. World Gastroenterol, 2016, 22(48):10512~10522.
[11] Koyama Y, Brenner DA. Liver inflammation and fibrosis[J].Clin Invest, 2017, 127(1):55~64.
[12] Murali AR, Gupta A, Brown K. Systematic review and meta-analysis to determine the impact of iron depletion in dysmetabolic iron overload syndrome and non-alcoholic fatty liver disease[J]. Hepatol Res, 2018, 48(3):E30~E41.